Pamela Douglas, MD, the Ursula Geller Professor for Research in Cardiovascular Diseases at Duke
Little Evidence of Valve Failure or Deterioriation
Among the 2,404 patients in the study who underwent TAVR, 34% survived 5 years. Similarly, 37% of the 313 patients whose valves were replaced in an open-heart surgery also survived 5 years. Twenty TAVR patients (0.8%) required a second valve procedure, and only 5 of the revisions arose from structural deteriorations of the valve.
The researchers found evidence that 3.7% of TAVR patients developed a condition in which the valve allowed blood to flow back into the heart, and this condition increased over time.
“This was seen in only a handful of patients, but it’s certainly something of concern and warrants further study,” Douglas says. “Overall, however, the findings from this carefully designed study demonstrate that there is little evidence of valve failure or deterioration for either TAVR or surgery using biologic valves.”